Publication | Closed Access
Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy
332
Citations
0
References
1999
Year
Peptide EngineeringPeptide SciencePeptide TherapeuticsInternal RadiotherapyMedicinal ChemistryRadiation MedicineReceptor-mediated Internal RadiotherapyTheranosticsPowerful β-Emitter 90YRadiopharmaceutical TherapySuperb Tumour-targeting PropertiesAnti-cancer AgentRadiation OncologyCancer ResearchMedicineRadionuclide TherapyCancer TreatmentPharmacologyPeptide TherapeuticOncologyGaiii Complex
A highly stable octacoordinated Y-DOTA-D-Phe-amide (see picture) allows the first use of the powerful β-emitter 90Y, coupled to a bioactive peptide, in internal radiotherapy of cancer. The same peptide labelled with the γ-emitter, 67Ga, shows improved biodistribution as a consequence of the hexacoordination of the GaIII complex with a pendant, ionised, acetic acid group.